<p>Clinical pharmacology is a discipline that includes education, research, and the implementation of knowledge into clinical practice, which ranges from precision dosing to therapeutic drug monitoring, and most recently, to the implementation of pharmacogenetic/pharmacogenomic (PGx) testing services to precisely administer drugs based on an individual's genetic make-up. In fact, PGx has become one of the core scientific pillars of the American Society for Clinical Pharmacology and Therapeutics (<i>ASCPT</i>) and its flagship journal, Clinical Pharmacology & Therapeutics (<i>CPT</i>). PGx implementation services have been rapidly adopted in academic healthcare centers throughout the United States and in Europe. These services are grounded in the availability of new genetic technologies and a wealth of scientific discoveries, generally describing the influence of genetic variants on drug responses in European ancestral populations. With the availability of PGx information, the Clinical Pharmacogenetics Implementation Consortium (<i>CPIC</i>) was established to develop guidelines on drug and dose selection for individuals based on their genetic information.<span><sup>1</sup></span> These guidelines, published in <i>CPT</i>,<span><sup>2, 3</sup></span> are increasingly being incorporated into clinical decision support systems, and used to advise providers on how to use PGx information in drug or dose selection.<span><sup>1</sup></span> However, despite of their widespread adoption in academic medical centers, there remains a resistance to PGx testing among healthcare providers. This can be attributed to various factors, such as cost of testing, requirements for expensive infrastructure, lack of provider education, and skepticism that there is any major benefit of testing.<span><sup>4</sup></span>